LamdaGen Corporation Launches Taiwan Diagnostic Subsidiary

MENLO PARK, Calif. and TAIPEI, Taiwan, March 18, 2015 /PRNewswire/ -- LamdaGen Corporation, a nano-technology platform company that provides LSPR based plasmonic sensors and systems for In Vitro Diagnostics (IVD), announced the opening of a wholly-owned subsidiary, LamdaGen Nanotechnology Taiwan Co., LTD. (LamdaGen Taiwan).

By far the fastest growing IVD region in the world is Asia ($11.8 billion in 2014), and within that market Point of Care Testing (POCT) is greatly outperforming regional growth. In Asia, LamdaGen Taiwan will commercialize a number of powerful, single-step, rapid and precisely quantitated POCT diagnostics with sensitivities into the low to sub-femtomolar range using a single sample drop.

LamdaGen Taiwan has entered into definitive agreements with Taipei Medical University Hospitals (TMU) for clinical trials of its digital POCT system including trials for important cancer, cardiovascular and infectious disease targets. Additionally, LamdaGen Taiwan is establishing a collaborative R&D facility within TMU and has also contracted with 3D Global Biotech, Inc. for GMP manufacturing of its nano-based POCT products in Taiwan.

"We are excited to bring a technology that meets several important diagnostic needs to Taiwan and Asia. LamdaGen's platform delivers high-sensitivity quantitative diagnostics in a simple, rapid and economical format for the IVD industry's next generation of POCT systems," stated Randy Storer, CEO of LamdaGen Corporation and Chairman of LamdaGen Nanotechnology Taiwan Co., LTD. "Our platform has the potential to transform disease management by enabling detection of previously undetectable biomarker levels, allowing for earlier disease detection and intervention."

LamdaGen's technology is based upon biophotonics, the science of generating, manipulating and harnessing light to image, detect and monitor biological and chemical interactions. The Company's micron-sized LSPR biosensors simply require a micro-LED, tiny optics and microfluidics to test and quantify diagnostic samples in fifteen minutes. The POCT platform is ideal for mobile applications and settings outside hospitals, as well as in centralized medical laboratories.

About LamdaGen Corporation
LamdaGen is a private nano-based technology platform company and the first to produce commercial LSPR (Localized Surface Plasmon Resonance) products. The products include highly sensitive nano-biosensors for In Vitro Diagnostics, including Central Laboratory based and Point of Care Testing (POCT) for human, veterinary and farm animal health. The nanotechnology platform is also purposed for additional scientific applications and products including drug discovery/development, life science research, food and water safety, and environmental and contaminant monitoring.

For more information, visit www.lamdagen.com, email info@lamdagen.com

Media Contact:
Alice Huang
650-571-5816
ahuang@lamdagen.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lamdagen-corporation-launches-taiwan-diagnostic-subsidiary-300052127.html

SOURCE LamdaGen Corporation